Literature DB >> 12177110

Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years.

Graça M Dores1, Catherine Metayer, Rochelle E Curtis, Charles F Lynch, E Aileen Clarke, Bengt Glimelius, Hans Storm, Eero Pukkala, Flora E van Leeuwen, Eric J Holowaty, Michael Andersson, Tom Wiklund, Timo Joensuu, Mars B van't Veer, Marilyn Stovall, Mary Gospodarowicz, Lois B Travis.   

Abstract

PURPOSE: To quantify the relative and absolute excess risks (AER) of site-specific second cancers, in particular solid tumors, among long-term survivors of Hodgkin's disease (HD) and to assess risks according to age at HD diagnosis, attained age, and time since initial treatment. PATIENTS AND METHODS: Data from 32,591 HD patients (1,111 25-year survivors) reported to 16 population-based cancer registries in North America and Europe (1935 to 1994) were analyzed.
RESULTS: Two thousand one hundred fifty-three second cancers (observed-to-expected ratio [O/E] = 2.3; 95% confidence interval [CI] = 2.2 to 2.4), including 1,726 solid tumors (O/E = 2.0; 95% CI, 1.9 to 2.0) were reported. Cancers of the lung (observed [Obs] = 377; O/E = 2.9), digestive tract (Obs = 376; O/E = 1.7), and female breast (Obs = 234; O/E = 2.0) accounted for the largest number of subsequent malignancies. Twenty-five years after HD diagnosis, the actuarial risk of developing a solid tumor was 21.9%. The relative risk of solid neoplasms decreased with increasing age at HD diagnosis, however, patients aged 51 to 60 years at HD diagnosis sustained the highest cancer burden (AER = 79.2/10,000 patients/year). After a progressive rise in relative risk and AER of all solid tumors over time, there was an apparent downturn in risk at 25 years. Temporal trends and treatment group distribution for cancers of the esophagus, stomach, rectum, female breast, bladder, thyroid, and bone/connective tissue were suggestive of a radiogenic effect.
CONCLUSION: Significantly increased risks of second cancers were observed in all HD age groups. Although significantly elevated risks of stomach, female breast, and uterine cervix cancers persisted for 25 years, an apparent decrease in relative risk and AER of solid tumors at other sites is suggested.

Entities:  

Mesh:

Year:  2002        PMID: 12177110     DOI: 10.1200/JCO.2002.09.038

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  131 in total

1.  Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study.

Authors:  Tara O Henderson; Kevin C Oeffinger; John Whitton; Wendy Leisenring; Joseph Neglia; Anna Meadows; Catherine Crotty; David T Rubin; Lisa Diller; Peter Inskip; Susan A Smith; Marilyn Stovall; Louis S Constine; Sue Hammond; Greg T Armstrong; Leslie L Robison; Paul C Nathan
Journal:  Ann Intern Med       Date:  2012-06-05       Impact factor: 25.391

2.  Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study.

Authors:  Paul Craig Nathan; Kirsten Kimberlie Ness; Martin Christopher Mahoney; Zhenghong Li; Melissa Maria Hudson; Jennifer Sylene Ford; Wendy Landier; Marilyn Stovall; Gregory Thomas Armstrong; Tara Olive Henderson; Leslie L Robison; Kevin Charles Oeffinger
Journal:  Ann Intern Med       Date:  2010-10-05       Impact factor: 25.391

3.  ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Authors:  Ralph M Meyer; Mary K Gospodarowicz; Joseph M Connors; Robert G Pearcey; Woodrow A Wells; Jane N Winter; Sandra J Horning; A Rashid Dar; Chaim Shustik; Douglas A Stewart; Michael Crump; Marina S Djurfeldt; Bingshu E Chen; Lois E Shepherd
Journal:  N Engl J Med       Date:  2011-12-11       Impact factor: 91.245

4.  Variables affecting survival after second primary lung cancer: A population-based study of 187 Hodgkin's lymphoma patients.

Authors:  Michael T Milano; Huilin Li; Louis S Constine; Lois B Travis
Journal:  J Thorac Dis       Date:  2012-02       Impact factor: 2.895

Review 5.  Late effects of therapy for Hodgkin's lymphoma.

Authors:  Michael Jacob Adams; Louis S Constine; Steven E Lipshultz
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

6.  Effect of organ size and position on out-of-field dose distributions during radiation therapy.

Authors:  Sarah B Scarboro; Marilyn Stovall; Allen White; Susan A Smith; Derek Yaldo; Stephen F Kry; Rebecca M Howell
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

Review 7.  Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.

Authors:  Annette E Hay; Ralph M Meyer
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

Review 8.  Relationship between Hodgkin's and non-Hodgkin's lymphomas.

Authors:  Rose-Marie Amini; Gunilla Enblad
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

9.  Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.

Authors:  Chunkit Fung; Sophie D Fossa; Michael T Milano; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

10.  Secondary malignancy in patients with sporadic neuroendocrine neoplasia.

Authors:  M Krausch; A Raffel; M Anlauf; M Schott; N Lehwald; A Krieg; F Kröpil; K Cupisti; W T Knoefel
Journal:  Endocrine       Date:  2013-03-14       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.